E Fund Management Co. Ltd. Reduces Stake in IQVIA Holdings Inc.

E Fund Management Co. Ltd. has significantly reduced its investment in IQVIA Holdings Inc. (NYSE:IQV) by 51.7% during the fourth quarter, as disclosed in its recent filing with the SEC. Following this reduction, E Fund Management now holds 2,024 shares of IQVIA's stock, having sold off 2,169 shares within the quarter. At the close of this financial period, the value of E Fund Management's stake in the medical research company stood at approximately $398,000.

In addition to E Fund Management, several other institutional investors have engaged in transactions involving IQV shares. Farther Finance Advisors LLC increased its position by 35.2% in the third quarter and now owns 407 shares valued at $96,000 after adding 106 shares. Similarly, Impax Asset Management Group plc raised its stake by 9.7%, owning 1,793,010 shares valued at $423,885,000 following a purchase of an additional 157,809 shares. Concurrent Investment Advisors LLC also increased its holdings by 5.6%, owning 5,679 shares valued at $1,346,000 after acquiring 301 more shares. Graypoint LLC boosted its stake by 6.3%, now holding 1,262 shares worth $299,000 following the purchase of 75 shares. Finally, Principal Financial Group Inc. raised its position by 0.8%, owning 209,021 shares valued at $49,532,000 after buying an additional 1,750 shares. Overall, institutional investors currently own 89.62% of IQVIA's stock.

IQVIA Stock Performance

The trading performance of IQVIA stocks has shown a modest increase, with the share price up by 3.4% recently. As of the latest trading session, NYSE IQV opened at $191.69. Over the past twelve months, IQVIA Holdings Inc. has recorded a low of $179.28 and a high of $261.72. The company's market capitalization is around $33.80 billion, and it has a price-to-earnings (P/E) ratio of 25.56 and a P/E growth (P/E/G) ratio of 1.99, with a beta of 1.50. The fifty-day moving average stands at $197.79, while the 200-day moving average is $212.87. The current ratio and quick ratio both sit at 0.84, and the debt-to-equity ratio is 2.12.

IQVIA recently released its earnings results on February 6th, reporting an earnings per share (EPS) of $2.90 for the quarter, which fell short of analysts' estimates of $3.11 by $0.21. The company achieved a return on equity of 28.81% and a net margin of 8.91%. Analysts project an EPS of 10.84 for the current fiscal year for IQVIA Holdings Inc.

Analyst Ratings for IQVIA

A number of analysts have provided insights regarding IQV shares. Truist Financial maintained a "buy" rating on IQVIA, increasing its price target to $263.00 from the previous $261.00. Citigroup, however, revised its target price down from $225.00 to $210.00 and rated the company as "neutral." Stifel Nicolaus also adjusted its target price, decreasing it from $273.00 to $261.00 while keeping a "buy" rating. Furthermore, Stephens initiated coverage on IQVIA with an "overweight" rating and set a target price of $250.00. Barclays followed suit by lowering its price target from $255.00 to $235.00 while maintaining an "overweight" rating. Overall, equity research analysts have delivered four hold ratings, seventeen buy ratings, and one strong buy rating for IQVIA, leading to an average rating of "Moderate Buy" and a consensus price target of $249.05.

About IQVIA Holdings Inc.

IQVIA Holdings Inc. specializes in providing advanced analytics, technology solutions, and clinical research services specifically tailored for the life sciences industry across various regions, including the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Investment, Finance, Stocks